Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the age linked neurodegenerative disorder with no disease modifying therapy currently available. The available therapy only offers short term symptomatic relief. Several hypotheses have been suggested for the pathogenesis of the disease while the molecules developed as possible therapeutic agent in the last decade, largely failed in the clinical trials. Several factors like tau protein hyperphosphorylation, amyloid-β (Aβ) peptide aggregation, decline in acetyl cholinesterase and oxidative stress might be contributing toward the pathogenesis of AD. Additionally, biometals dyshomeostasis (Iron, Copper, and Zinc) in the brain are also reported to be involved in the pathogenesis of AD. Thus, targeting these metal ions may be an effective strategy for the development of a drug to treat AD. Chelation therapy is currently employed for the metal intoxication but we lack a safe and effective chelating agents with additional biological properties for their possible use as multi target directed ligands for a complex disease like AD. Chelating agents possess the ability to disaggregate Aβ aggregation, dissolve amyloid plaques, and delay the cognitive impairment. Thus there is an urgent need to develop disease modifying therapeutic molecules with multiple beneficial features like targeting more than one factor responsible of the disease. These molecules, as disease modifying therapeutic agents for AD, should possess the potential to inhibit Aβ-metal interactions, the formation of toxic Aβ aggregates; and the capacity to reinstate metal homeostasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“The first active immunotherapy trial targeting Aβ due to meningoencephalitis observed in a number of patients was terminated (Orgogozo et al., 2003).”
BackgroundTerry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585
Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-β peptide
Faller, P., & Hureau, C. (2009) · Dalton Trans. · doi:10.1039/b813398k · Cited by 530 · cited 1×
“Coordination number and binding affinity of the Cu+2 and Zn+2 ions toward Aβ peptide and metalloproteins and found less dissociation constant value for Aβ peptide than metalloproteins have been investigated (Faller and Hureau, 2009).”
BackgroundBiological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497 · cited 1×
“Having said that, the classical chelation therapy may not be the simple answer to AD, rather existing molecules and/or newer agents will have to be accessed for restoring metal deregulation (Barnham and Bush, 2014).”
BackgroundIdentifying and validating biomarkers for Alzheimer's disease
Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484 · cited 1×
“However, an ideal biomarker should be capable of distinguishing AD from other types of dementia (Humpel, 2011).”
BackgroundAmyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Midlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Alzheimer's disease, metal ions and metal homeostatic therapy
Zatta, P., Drago, D., Bolognin, S., & Sensi, S. L. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.002 · Cited by 369
Di Vaira, M., Bazzicalupi, C., Orioli, P., Messori, L., Bruni, B., & Zatta, P. (2004) · Inorganic Chemistry · doi:10.1021/ic0494051 · Cited by 292
Choi, J.-S., Braymer, J. J., Nanga, R. P. R., Ramamoorthy, A., & Lim, M. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006091107 · Cited by 264
New Insights on How Metals Disrupt Amyloid β-Aggregation and Their Effects on Amyloid-β Cytotoxicity
Yoshiike, Y., Tanemura, K., Murayama, O., Akagi, T., Murayama, M., Sato, S., Sun, X., Tanaka, N., & Takashima, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010706200 · Cited by 244
Tea consumption and cognitive impairment and decline in older Chinese adults
Ng, T.-P., Feng, L., Niti, M., Kua, E.-H., & Yap, K.-B. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.1.224 · Cited by 236
Structural Aspects of Flavonoids as Inhibitors of Human Butyrylcholinesterase
Katalinić, M., Rusak, G., Domaćinović Barović, J., Šinko, G., Jelić, D., Antolović, R., & Kovarik, Z. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.09.041 · Cited by 206
Small Molecule Modulators of Copper-Induced Aβ Aggregation
Hindo, S. S., Mancino, A. M., Braymer, J. J., Liu, Y., Vivekanandan, S., Ramamoorthy, A., & Lim, M. H. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907045h · Cited by 203
Mandel, S., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.06.001 · Cited by 164 · cited 2×
“biometals might be playing a crucial role in the pathogenesis of AD (Zhang, 2005; Mandel et al., 2007; Henry et al., 2010; DeToma et al., 2012; Kotler et al., 2014; Pfaender and Grabrucker, 2014).”
BackgroundRodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Abraham, J., & Johnson, R. W. (2009) · Rejuvenation Research · doi:10.1089/rej.2009.0888 · Cited by 131
Youdim, M. B. H., Fridkin, M., & Zheng, H. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.08.023 · Cited by 128
Characterization of biometal profiles in neurological disorders
Pfaender, S., & Grabrucker, A. M. (2014) · Metallomics · doi:10.1039/c4mt00008k · Cited by 117 · cited 1×
“biometals might be playing a crucial role in the pathogenesis of AD (Zhang, 2005; Mandel et al., 2007; Henry et al., 2010; DeToma et al., 2012; Kotler et al., 2014; Pfaender and Grabrucker, 2014).”
BackgroundEffects of Clioquinol on Metal-Triggered Amyloid-β Aggregation Revisited
Mancino, A. M., Hindo, S. S., Kochi, A., & Lim, M. H. (2009) · Inorganic Chemistry · doi:10.1021/ic9014256 · Cited by 102
Xu, P., Zhang, M., Sheng, R., & Ma, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.045 · Cited by 92
Bendova, P., Mackova, E., Haskova, P., Vavrova, A., Jirkovsky, E., Sterba, M., Popelova, O., Kalinowski, D. S., Kovarikova, P., Vavrova, K., et al. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100125t · Cited by 73 · cited 1×
“The chelating agents must possess properties like having moderate binding affinity for copper, zinc and iron metals, ability to cross BBB and should not toxic (Bendova et al., 2010).”
Background
Cited by
Heavy metal toxicity: An update of chelating therapeutic strategies
Kim, J.-J., Kim, Y.-S., & Kumar, V. (2019) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2019.05.003 · Cited by 635
Angelova, P. R., Esteras, N., & Abramov, A. Y. (2021) · Medicinal Research Reviews · doi:10.1002/med.21712 · Cited by 287
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
González, J. F., Alcántara, A. R., Doadrio, A. L., & Sánchez-Montero, J. M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1623201 · Cited by 98
Liquid-liquid phase separation in Alzheimer’s disease
Fu, Q., Zhang, B., Chen, X., & Chu, L. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02407-3 · Cited by 33
“In recent years, due to the frustration of traditional strategies for developing treatment of AD in clinical trials, targeting metal ions has become a new strategy for treating AD [89].”
Metadata
- Authors
- Sharma, A., Pachauri, V., & Flora, S. J. S.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-15
- Volume
- 9
- Pages
- 1247-1247
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2901073430
- Cited by
- 67
- References
- 29
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.